The REDUCE trial of 6729 men who were considered high risk for prostate cancer, due to age, elevated prostate-specific antigen (PSA), and a previous suspicion of prostate cancer, found a 23% relative risk reduction of developing prostate cancer among those treated with dutasteride for four years compared to placebo5. Here, KLK3 is linked to prostate cancer.